Experimental drug seems very effective for frequent menopausal hot flushesBMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j1685 (Published 04 April 2017) Cite this as: BMJ 2017;357:j1685
- Ingrid Torjesen
An experimental drug has been found to cut the number of menopausal hot flushes by almost three quarters in an early trial reported in the Lancet.1
The trial, funded by the UK Medical Research Council and the National Institute for Health Research, tested a neurokinin 3 receptor antagonist (MLE4901), originally developed by AstraZeneca and licensed to Millendo Therapeutics, in women who experienced severe flushing as a menopausal symptom.
Postmortem studies of brain tissue from post-menopausal women have shown that it contains elevated levels of neurokinin B, and researchers at Imperial College London …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial